Jsbm Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.98 M
About Jsbm Pharma
Jsbm Pharma Private Limited (JPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 October 2021 (Three years and three months 10 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.98 M.
Sumit Agrawal, Ankit Agrawal, Barkha Agarwal, and One other member serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MP2021PTC058206
-
Company No.
058206
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
29 Oct 2021
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Jsbm Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumit Agrawal
|
Director | 29-Oct-2021 | Current |
|
Ankit Agrawal
|
Director | 29-Oct-2021 | Current |
|
Barkha Agarwal
|
Director | 29-Oct-2021 | Current |
|
Rani Agrawal
|
Director | 29-Oct-2021 | Current |
Financial Performance of Jsbm Pharma.
Jsbm Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jsbm Pharma?
Unlock access to Jsbm Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Fair Deal Remedies Private LimitedSumit Agrawal and Ankit Agrawal are mutual person
Charges (Loans)
₹0.98 M
₹0
Charges Breakdown by Lending Institutions
- Idbi Bank Limited : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Mar 2023 | Idbi Bank Limited | ₹0.98 M | Open |
How Many Employees Work at Jsbm Pharma?
Jsbm Pharma has a workforce of 0 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jsbm Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jsbm Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.